أصول متداولة تغيير تاريخ
AbbVie USD 33.53B 4.47B 2026-03
Bristol-Myers Squibb USD 27.21B 2.18B 2026-03
Galectin Therapeutics USD 27.29M 1.83M 2024-06
Gilead Sciences USD 18.64B 1.25B 2026-03
Immunic USD 188.76M 165.89M 2026-03
Incyte USD 5.48B 460.36M 2026-03
Merck USD 35.02B 8.5B 2026-03